financetom
Business
financetom
/
Business
/
LPL Financial Makes $2.7 Billion Deal to Acquire Wealth Manager Commonwealth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LPL Financial Makes $2.7 Billion Deal to Acquire Wealth Manager Commonwealth
Mar 31, 2025 6:55 AM

09:32 AM EDT, 03/31/2025 (MT Newswires) -- LPL Financial ( LPLA ) will acquire wealth management firm Commonwealth Financial Network in a $2.7 billion deal that will expand LPL's advisory staff.

Commonwealth "supports" about 2,900 independent financial advisers managing $285 billion in brokerage and advisory assets, the companies said in a statement Monday. The deal is expected to close in the second half of the year.

"Commonwealth Advisors will continue to benefit from their relationships with our team members, all while taking full advantage of LPL's scale and platform," said Wayne Bloom, chief executive of Commonwealth.

Bloom will head up a new office of advisor advocacy for LPL, "charged with further elevating the service experience for LPL's growing network of advisors," the companies said.

LPL has been on a deal-making trend, eyeing mergers and acquisitions as a key part of its growth strategy. Earlier in March, LPL closed its purchase of The Investment Center, with 160 "high-performing" advisers added to its network. Last year, LPL purchased Atria Wealth Solutions.

"Rising cost and complexity is making it harder for smaller players to effectively compete," LPL said in an investor presentation Monday. "We believe consolidation can drive value creation."

LPL's shares are up more than 3% so far this year, but were trading lower in pre-market activity. LPL separately said that it is selling $1.5 billion in shares for the Commonwealth acquisition, while bookrunner Morgan Stanley has an option to buy another $225 million. LPL said it will use corporate cash, debt and equity to fund the deal, putting it above the midpoint of the target leverage range of 1.5 times to 2.5 times.

The company will "pause share repurchases, resulting in pro-forma net leverage within management's target leverage range," LPL said in the presentation. In 2024, LPL made $170 million in share repurchases, according to its fourth-quarter financials.

LPL said it sees "low single-digit accretion" to run-rate adjusted earnings per share by the end of 2026.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Transcode Therapeutics (RNAZ) Stock Is Down 60%
Why Transcode Therapeutics (RNAZ) Stock Is Down 60%
Jul 23, 2024
Transcode Therapeutics Inc ( RNAZ ) shares are trading lower by 62% to $0.30 during Tuesday’s session after the company announced pricing of its public offering. The public offering of 10 million shares of its common stock will be at $0.30 per share, aiming to raise $3 million before deducting expenses. The offering is set to close on July 24,...
Sector Update: Consumer
Sector Update: Consumer
Jul 23, 2024
01:24 PM EDT, 07/23/2024 (MT Newswires) -- Consumer stocks were softer Tuesday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) shedding 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) fractionally lower. Redbook US same-store sales rose by 4 .9% from a year earlier in the week ended July 20 after a 4.8% year-over-year increase in the...
Hospital Chain Operator HCA Healthcare Says Positive Q2 Earnings Reflect Strong Demand For Services, Issues Upbeat Annual Outlook
Hospital Chain Operator HCA Healthcare Says Positive Q2 Earnings Reflect Strong Demand For Services, Issues Upbeat Annual Outlook
Jul 23, 2024
On Tuesday, HCA Healthcare Inc. ( HCA ) reported second-quarter revenues of $17.49 billion, up from $15.86 billion a year ago and beating the consensus of $17.05 billion. The hospital chain reported adjusted EPS of $5.50, up from $4.29 a year ago, beating the consensus of $5.36. “The company’s results for the second quarter were positive and reflected strong demand for...
Cellectar Shares Fall as Updated Data For Investigational Radiotherapy Shows Drop in Major Response Rate
Cellectar Shares Fall as Updated Data For Investigational Radiotherapy Shows Drop in Major Response Rate
Jul 23, 2024
01:26 PM EDT, 07/23/2024 (MT Newswires) -- Cellectar Biosciences ( CLRB ) shares were down nearly 19% in recent Tuesday trading after the company released updated data for its investigational radiotherapy Iopofosine I 131, showing a drop in major response rate. As of the May 31 cutoff, Iopofosine I 131 was found to have a major response rate of 56.4%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved